Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

From Avastin To Zevalin: ODAC’s Most Memorable Moments

Apr 22 2013

• By Sue Sutter

Related Content

<i>Avastin</i> Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints

Jul 11 2011

Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says

Sep 13 2005

OrBec Future In Doubt: Cmte. Calls For Further Study, But Firm Is Out Of Funds

May 21 2007

EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials

May 14 2007

Tempers Flare At ODAC Meeting, And Pazdur Must Call "Order In The Court"

Dec 06 2010

Idec Zevalin Clears Cmte.: Non-Refractory Use May Be Accelerated Approval

Sep 17 2001

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window